Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 33Neoplasms 18Colorectal Neoplasms 3Skin Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Solid Tumor 1Skin Diseases 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Cancer Metastatic 1Biliary Tract Neoplasms 1Advanced BRAF-mutant Cancers 1

Interventions

Injections 12pembrolizumab 11Nivolumab 9Paclitaxel 8senaparib 7Docetaxel 7Cisplatin 6Capecitabine 6Gemcitabine 5toripalimab 4tislelizumab 4atezolizumab 4Ipilimumab 4Carboplatin 4Bevacizumab 4sintilimab 3Rifampin 3Oxaliplatin 3Itraconazole 3130-nm albumin-bound paclitaxel 3zimberelimab 2pertuzumab 2osimertinib 2ontuxizumab 2navoximod 2magrolimab 2fluzoparib 2famitinib 2durvalumab 2camrelizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumor × Vemurafenib × Clear all
NCT03781219 2023-05-31

A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation

Shanghai Kechow Pharma, Inc.

Phase 1 Unknown
45 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡